Abstract
Ceftizoxime (CZX) is a new semisynthetic cephalosporin which is structually similar to cefotiam and cefotaxime. Bacteriological and clinical studies were performed in the urological infections. The results obtained were as follows:
1. Minimum inhibitory concentration of CZX against 146 strains isolated from urinary tract infections was measured. In 106/ml inoculum size, CZX showed excellent antibacterial activity against E. coli, P. mirabilis, Klebsiella and superior activity against P. vulgaris and Serratia. P. aeruginosa, P. putida and Acinetobacter were inhibited by wide ranges of CZX concentration.
2. Thirty-three cases with urogenital infections were treated with CZX, mostly by intravenous injection of a daily dose of 2.0 g. These cases consisted of 31 complicated urinary tract infections and 2 acute prostatitis. Of 33 cases, excellent response was obtained in 12, moderate response in 15, and poor response in 6 cases, respectively. Thirty out of 35 organisms isolated from complicated urinary tract infections were eradicated after the treatment.
3. No side effect was seen throughout this series.
